Consistent with these observed therapeutic benefits, the combination therapy was associated with an expansion of CD4+ T, CD8+ T, CD3-NK1.1+ (NK), and CD3+NK1.1+ (NKT cells, NKT) cells in the blood day 13 post tumor implantation (Fig. 3a, f–i and Supplementary Table 2). The gene discussed is CD8A; the disease is neoplasm.